Protein tyrosine kinase 6 (PTK6) is a non-receptor tyrosine kinase expressed in epithelial cancers. Disruption of Ptk6 decreases azoxymethane-induced colon tumorigenesis in mice by preventing signal transducer and activator of transcription 3 activation. Relocalization of PTK6 in prostate cancers contributes to increased growth. Although not expressed in normal breast or ovary, PTK6 promotes anchorage-independent survival of breast and ovarian tumor cells. We identified several potential PTK6 substrates in the human SW620 colon cancer cell line using mass spectrometry, including FAK (focal adhesion kinase). We show that FAK is a direct substrate of PTK6 in vitro and in vivo. Expression of membrane-targeted active PTK6 (Palm-PTK6-YF) induces constitutive activation of FAK and cell morphology changes, which are independent of SRC family kinases in Src À / À , Yes À / À , Fyn À / À (SYF) mouse embryonic fibroblasts (MEFs). Palm-PTK6-YF expressing SYF cells are transformed and overcome contact inhibition, form colonies in transformation assays, proliferate in suspension and form tumors in a xenograft model. Expression of FAK and Palm-PTK6-YF in Fak À / À MEFs synergistically activates AKT and protects cells against anoikis. However, expression of Palm-PTK6-YF in Akt1/2 À / À MEFs fails to protect cells from anoikis, indicating AKT is critical in PTK6 and FAK-mediated survival signaling. In a conditional Pten knockout murine prostate cancer model, we identify prostate epithelial cells with enhanced activation of endogenous PTK6 and FAK at the plasma membrane. Knockdown of PTK6 in the PC3 human prostate cancer cell line disrupts FAK and AKT activation and promotes anoikis, which can be rescued by exogenous expression of FAK. Our data reveal important roles for a PTK6-FAK-AKT signaling axis in promoting anchorage-independent cell survival.
INTRODUCTION
Protein tyrosine kinase 6 (PTK6), (also called BReast tumor Kinase or SRC-related Intestinal Kinase), is an intracellular non-receptor tyrosine kinase. 1, 2 Lack of an amino-terminal myristoylation sequence leads to increased flexibility in intracellular localization, and PTK6 can be found at the membrane, the cytoplasm and the nucleus. [3] [4] [5] A variety of proteins have been identified as PTK6 substrates, including the RNA binding proteins Sam68, 3 SLM-1, SLM-2, 6 the transcription factors STAT3 (signal transducer and activator of transcription 3), 7 STAT5b, 8 b-catenin, 9 scaffold proteins BKS/STAP2, 10 paxillin, 11 p130CAS, 5 epidermal growth factor receptor, 12 the serine/threonine kinase AKT, 13 and a guanosine triphosphatase activating protein p190RhoGAP. 14 Although PTK6 is not expressed in the normal mammary gland, it is frequently overexpressed in human breast tumors. 15, 16 Increased expression or relocalization of PTK6 is also detected in other types of human cancer including colon, 17 prostate, 4 head and neck cancer, 18 as well as serous carcinoma of ovary. 19 Several recent studies revealed a role for PTK6 in cell proliferation and survival in vivo. In an azoxymethane/dextran sodium sulfate murine colon cancer model, disruption of Ptk6 prevents activation of STAT3 and decreases azoxymethane-induced colon tumorigenesis in mice. 20 In a PTK6 transgenic mouse model, activation of a p38 MAPK pro-survival signaling pathway delays involution of mouse mammary gland. 16 In addition, PTK6 is a critical regulator of insulin-like growth factor-1-mediated anchorage-independent survival of breast and ovarian tumor cells, but the downstream molecular mechanisms are still not clear. 21 Focal adhesion kinase (FAK) was identified as a highly phosphorylated protein localized in focal adhesion contacts of normal cells (reviewed in Parsons 22 ). Its activity is regulated by integrin-mediated cell adhesion, as well as activation of growth factor receptor and G-protein linked receptor signaling (reviewed in Schaller 23 ). FAK is involved in various cell functions including proliferation, survival, motility and invasion (reviewed in Schaller 23 ; Schlaepfer and Mitra 24 ). It regulates cell survival and apoptosis through several different mechanisms. FAK is able to activate phosphatidylinositol 3-kinase/AKT signaling to promote survival of fibroblasts. 25 Depending upon the cellular context, FAK forms signaling complexes with Paxillin or p130CAS to transmit distinct survival signals to fibroblasts and epithelial cells. 26 Recently, nuclear FAK was reported to promote cell survival by facilitating p53 turnover via enhanced Mdm2-dependent p53 ubiquitination. 27 AKT, a serine threonine protein kinase that has critical roles in cell proliferation, survival, angiogenesis and metabolism, is frequently activated in different types of human cancers (reviewed in Manning and Cantley 28 ) . It is downstream of growth factor receptors and phosphatidylinositol 3-kinase, and regulates cell survival through multiple mechanisms including inhibition of proapoptotic proteins such as Bad and FoxO transcription factors and activation of pro-survival genes through the IkB kinase/nuclear factor kappa-light-chain-enhancer of activated B cells signaling pathway. 28, 29 AKT regulates cell cycle and proliferation through direct phosphorylation of p21 WAF1/CIP1 and p27 KIP1 and indirect transcriptional regulation by inhibition of FoxO transcription factors. 30, 31 AKT itself is sufficient to suppress anoikis, a form of programmed cell death induced by the loss of cell-matrix interactions. 32 Anoikis resistance and anchorage independence are critical for a tumor cell to invade adjacent tissue, giving rise to metastases (reviewed in Guadamillas et al. 33 ).
We demonstrate FAK is a direct substrate of PTK6, and PTK6mediated tyrosine phosphorylation of FAK and subsequent AKT activation promotes resistance to anoikis. We show that membrane-associated active PTK6 transforms SYF cells in the absence of SRC family kinases. Knockdown of PTK6 in prostate cancer cells impairs their ability to maintain FAK and AKT activation under non-adherent growth condition, resulting in apoptosis. These studies delineate a role for a PTK6-FAK-AKT signaling axis in anchorage-independent cell survival, and enhance our understanding of the contributions of PTK6 to cancer cell signaling.
RESULTS

Mass spectrometry analysis revealed several candidate PTK6 substrates
Mice lacking Ptk6 are resistant to azoxymethane-induced colon tumorigenesis probably due to reduced activation of the PTK6 substrate STAT3, 7, 20 but other mechanisms may also exist. 7 Therefore, we tried to identify additional potential PTK6 substrates using liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) of differentially tyrosine phosphorylated proteins in the presence of active PTK6. SW620 cells were transfected with vector or PTK6-YF for 24 h, serum starved for 48 h to reduce basal protein tyrosine phosphorylation and then cells were serum stimulated for 1, 3 and 5 h. Mutation of the regulatory tyrosine 447 at the carboxy-terminus of PTK6 to phenylalanine prevents autoinhibition and promotes constitutive activation. 3, 34 Cells that were serum stimulated for 5 h displayed the least basal tyrosine phosphorylation in vector control cells, and a distinct set of proteins were tyrosine phosphorylated in the presence of active PTK6 (Supplementary Figure S1A) . A large-scale anti-phosphotyrosine (PY) immunoprecipitation (IP) was performed with lysates harvested at the 5 h time point, and three distinct bands at B120, 80 and 68 kDa were enriched from cells expressing active PTK6, which were then excised from SDS-polyacrylamide gel electrophoresis gels and digested with trypsin for LC/MS/MS sequencing (Supplementary Figure S1B ). Several novel candidate PTK6 substrates including FAK, CUL4, the dead box proteins DDX5 and DDX17, and Hsp70 along with confirmed substrates of PTK6 such as Sam68, Paxillin, PSF and p130CAS 3, 5, 11, 35 were identified. PTK6 directly phosphorylates FAK independent of SRC family kinases FAK was identified as a potential PTK6 substrate by LC/MS/MS sequencing, and it has crucial roles in suppressing anoikis and promoting anchorage-independent survival in a variety of cell types. 3, [25] [26] [27] 36, 37 FAK is tyrosine phosphorylated by SRC at several tyrosine residues including 576/577, 861 and 925. Phosphorylation of FAK tyrosine residues 576/577 is important for maximum activation, while phosphorylation of tyrosine residue 925 serves as a high-affinity Grb2 binding site (reviewed in Schlaepfer and Mitra 24 ). As phosphorylation of FAK at several tyrosine residues is important for its activation and downstream signaling, we investigated if FAK is a direct substrate of PTK6. In an in vitro kinase assay, tyrosine phosphorylation of FAK is increased in the presence of PTK6 and ATP ( Figure 1a ). We detected phosphorylation of FAK tyrosine residue 861 in vitro using LC/MS/MS ( Figure 1b ). Expression of active PTK6 in HEK-293 and SW620 cells induces the tyrosine phosphorylation of FAK, as evident by FAK IP followed by immunoblotting analysis with anti-phosphotyrosine antibodies (Figure 1c ). In addition, glutathione S-transferase (GST) pull down assays using PTK6 GST fusion proteins containing full length PTK6, or its SH2, SH3 or SH2/SH3 domains showed that PTK6 interacts with FAK primarily through its SH2 domain, which recognizes phosphorylated tyrosine residues on FAK ( Figure 1d ).
As FAK can be phosphorylated by SRC kinase, 38 the SYF (Src À / À , Yes À / À , Fyn À / À ) mouse embryonic fibroblast (MEF) cell line was used to exclude interference by SRC family kinases. Following serum stimulation, higher tyrosine phosphorylation of FAK was observed in SYF cells stably expressing PTK6-YF or PTK6-WT, compared with cells expressing kinase dead PTK6-KM or vector controls ( Figure 1e , FAK IP; 1f). This was also observed using phosphorylation-specific FAK antibodies PY925 or PY576/Y577 ( Figure 1e ). Interestingly, FAK reaches the peak of tyrosine phosphorylation at the 10 min time point in PTK6-WT or PTK6-YF expressing cells, correlating with the activation of PTK6, monitored by phosphorylation of PTK6 tyrosine residue 342 (Figure 1e , P-PTK6). These data suggest that PTK6-induced tyrosine phosphorylation on FAK is dependent on the kinase activity of PTK6, and independent of SRC family kinases.
Membrane-targeted active PTK6 induces constitutive FAK activation and transformation of SYF fibroblasts
Although PTK6 is primarily cytoplasmic in the PC3 prostate cancer cell line, the active pool of PTK6 that is phosphorylated on tyrosine residue 342 is associated with membrane compartments. 5 SYF cells stably expressing membrane-targeted PTK6 with mutation of the carboxy-terminal regulatory tyrosine (Palm-PTK6-YF) have constitutively active PTK6, even in cells that are serum starved for 48 h (Figure 2a , 0 time point, P-PTK6, Palm-YF). FAK is constitutively phosphorylated at tyrosine residues 576, 577 and 925 in Palm-YF expressing cells (Figure 2a ). A long exposure of the immunoblot for FAK phosphorylated at tyrosine residue 925 shows that Y925 phosphorylation increases upon serum stimulation in vector control cells and cells expressing untargeted PTK6-YF (130 kDa band). Immunostaining of SYF cells expressing untargeted PTK6-YF shows that it is capable of inducing formation of focal adhesions containing increased phospho-FAK and phospho-Paxillin (Figure 2b , YF). However, expression of membrane-targeted Palm-PTK6-YF dramatically changed cell morphology, and led to formation of numerous thin, long actin-bundle protrusions around plasma membrane, with tyrosine phosphorylated FAK and Paxillin at the tip of each protrusion (Figure 2b , Palm-PTK6-YF).
Next, we investigated the behavior of SYF cells with constitutively active PTK6 and FAK. While wild-type SYF cells form a single-cell layer due to contact inhibition after confluence, cells expressing Palm-PTK6-YF overcome contact inhibition and continue to grow after confluence. Cells expressing untargeted PTK6-YF are more densely packed than vector control cells, but they do not lose contact inhibition (Figure 3a ). This observation is consistent with the growth curve data, showing that Palm-PTK6-YF expressing cells continue to proliferate after cells reach confluence at day 5, while preconfluent growth rates are similar for the three SYF cell lines ( Figure 3b ). Anchorage-independent growth of SYF cells in soft agar assays is augmented when Palm-PTK6-YF is expressed and to a lesser extent when untargeted PTK6-YF is present (Figures 3c and d ). Foci-forming ability was also measured by performing transformation assays. Only Palm-PTK6-YF expressing SYF cells acquired the capacity to form foci on plates when mixed with the non-tumorigenic parental SYF cells ( Figure 3e ). Resistance to anoikis is another trait of transformed cells. SYF cells expressing Palm-PTK6-YF overcome anoikis and continue to proliferate in suspension. Significantly larger and more cell spheres were observed in Palm-PTK6-YF expressing cells at 6 days after seeding on poly-2-hydroxyethyl methacrylate (poly-HEMA) coated plates ( Figure 3f ). Immunoblotting of lysates prepared from cells following 72 h of growth in suspension showed highly activated PTK6 (P-PTK6) and FAK (PY567/Y577, PY925) in Palm-PTK6-YF expressing cells, accompanied by increased AKT activation (Thr308, Ser473) and decreased levels PTK6 and FAK provide synergistic protection against anoikis To further characterize the roles of FAK and AKT in PTK6-mediated resistance to anoikis, Fak À / À and Akt1/2 À / À MEFs were utilized. The absence of endogenous FAK or AKT was confirmed by immunoblotting ( Figure 4a ). While expression of Palm-PTK6-YF (PYF) or FAK alone protects Fak À / À MEFs against anoikis, co-expression of Palm-PTK6-YF and FAK exerts synergistic effects in protecting cells from anoikis, leading to increased viability and formation of larger spheres after 6 days of growth on poly-HEMA coated plates (Figures 4b and c ). Indeed, Fak À / À MEFs stably expressing Palm-PTK6-YF and FAK acquire resistance to anoikis and continue proliferating under suspended conditions over a 14day period (data not shown). Immunoblotting of lysates prepared from cells following 72 h of growth in suspension showed that co-expression of Palm-PTK6-YF and FAK induces higher FAK activation (PY576/Y577) even under suspended conditions, resulting in substantially higher levels of AKT activation (phospho-Thr308, phospho-Ser473) and lower levels of CC3 and p27 ( Figure 4d ). AKT has important roles in regulating cell survival and growth (reviewed in Xu et al. 39 ). Expression of Palm-PTK6-YF in Akt1/2 À / À MEFs fails to protect them from anoikis (Figure 4e ). Both control Akt1/2 À / À MEFs and Palm-PTK6-YF expressing Akt1/2 À / À MEFs undergo apoptosis when grown under nonadherent growth conditions, as measured by a cell viability assay (Figure 4e ). This is consistent with immunoblotting analysis showing the same level of CC3 induction after 24 h suspension in both MEFs, although increased FAK phosphorylation (PY576/Y577, PY925) was observed in Palm-PTK6-YF expressing MEFs (Figure 4f ). Our data suggest AKT is a critical downstream 
Knockdown of PTK6 in prostate cancer cells promotes anoikis
Active PTK6 is associated with membrane compartments in cultured tumor cells, but the status and localization of activated PTK6 in vivo in tumors are not clear. We utilized a PTEN flox/flox , Probasin-Cre transgenic murine prostate cancer model, which forms metastatic prostate tumors at the age of 6 months. 40 Immunohistochemistry showed highly induced PTK6 activation at the membrane in a group of Pten-null prostate cells, which possess enlarged nuclei and substantial cytoplasm (Figure 5a ). Activated P-FAK signaling was also observed in the same group of cells, providing in vivo evidence of the tight relationship between PTK6 and FAK signaling in diseased prostate (Figure 5a ). These cells, with activated PTK6 and P-FAK, were not observed in agematched control prostates from PTEN flox/flox mice lacking Cre (data not shown).
Next, we investigated the role of PTK6 in protecting human prostate cancer cells from anoikis. Endogenous PTK6 was knocked down in PC3 cells using small interfering RNAs (siRNAs) against PTK6 (Figure 5b, PTK6 ). Although knockdown of PTK6 did not affect FAK activation when cells were grown under adherent conditions (Plate), decreased FAK activation was observed in suspended PTK6 knockdown cells grown on poly-HEMA coated plates, indicating that a primary role of PTK6 is to maintain the level of FAK activation when cells are detached from the extracellular matrix (Figure 5b , PY576/Y577, PY925). Decreased FAK activation was accompanied by impaired AKT activation and increased expression of CC3 (Figure 5b , Thr308, Ser473, CC3). The population of PC3 cells treated with scrambled siRNAs (si-Control) reached a balance between proliferation, cell cycle arrest and cell death under suspended growth conditions, as measured by cell viability assays performed from day 1 to day 8 (Figure 5c ). Knockdown of PTK6 triggered apoptosis, and only 20% of the cells were viable after 8 days of growth on poly-HEMA coated plates (Figure 5c ). Importantly, overexpression of hemagglutinin (HA) epitope-tagged FAK (HA-FAK) in PC3 cells rescued anoikis induced by PTK6 knockdown (Figures 5d and e ). FAK promotes survival of control-siRNA treated cells grown in suspension on poly-HEMA (Figure 5e , si-Control þ FAK), and restores survival of cells with PTK6 knockdown to the levels of control PC3 cells (Figure 5e , si-PTK6 þ FAK). These data demonstrate critical roles for PTK6/FAK signaling in regulating the anchorage-independent survival of prostate cancer cells.
Two breast cancer cell lines MBA-MD-231 and T47D, which express PTK6, were also utilized to investigate whether PTK6 generally promotes resistance to anoikis in cancer cells. Anoikis assays demonstrated that knockdown of PTK6 led to increased anoikis in MBA-MD-231 cells grown under non-adherent conditions on poly-HEMA coated plates (Supplementary Figure S2A ). This was accompanied by decreased FAK/AKT survival signaling and increased levels of CC3, which was also observed in T47D cells ( Supplementary Figure S2B, C) .
PTK6 is primarily responsible for resistance of PC3 cells to anoikis As FAK can be phosphorylated by SRC kinase, 38 and FAK/SRC signaling is involved in regulating survival and anoikis of human intestinal epithelial cells, 41 we investigated whether PTK6 or SRC is more relevant for anoikis resistance in prostate cancer cells. Two different siRNAs against SRC were used to knockdown endogenous SRC in PC3 cells (Figure 6a ). Knockdown of SRC does cause a slight decrease of the percentage of live cells compared with control siRNAs treated cells, (Figure 6c ). However, survival of PTK6-siRNA treated cells is much more reduced after 120 h of growth on poly-HEMA coated plates, indicating that PTK6 is primarily responsible for protecting prostate cancer cells against anoikis (Figure 6c ). In addition, knockdown of PTK6 and SRC together does not show a synergistic effect in inducing anoikis, and is comparable to knockdown of PTK6 alone (Figure 6c ). To demonstrate the role of FAK in regulating anoikis, siRNAs against FAK were used to knockdown endogenous FAK in PC3 cells ( Figure 6b ). Knockdown of FAK efficiently induces anoikis, and the level is close to that of PTK6 knockdown cells (Figure 6c ). This is consistent with our hypotheses that FAK is a critical downstream target of PTK6 in protecting cells from anoikis.
DISCUSSION
PTK6 shares structural similarity with SRC kinases. 42 PTK6 tyrosine residue 342 is conserved between PTK6 and SRC, and its phosphorylation serves as a marker for PTK6 activation, as it causes the activation loop to move out of the substrate-binding site, therefore allowing access to substrates. 34 Phosphorylation of the conserved carboxy-terminal tyrosine residue 447 results in autoinhibition due to the binding to its own SH2 domain. 34 Mutation of tyrosine residue 447 to phenylalanine (PTK6-YF) increases kinase activity, as there is no autoinhibition. However, the activity of untargeted PTK6-YF can still be downregulated by serum starvation (Figure 1e ). Interestingly, membrane-targeted PTK6 (Palm-PTK6-YF) is not downregulated by serum starvation (Figure 2a ), and represents an authentic constitutively active form of PTK6. This could contribute to involvement of PTK6 in multiple receptor-signaling pathways including epidermal growth factor receptor, HER2, insulin-like growth factor-1R, MET and integrin. 5, 12, 21, 43, 44 Our data show that constitutive activation of PTK6 transforms SYF MEFs, as manifested by their ability to overcome contact PC3 cells were transfected with siRNAs against PTK6 or control siRNAs for 24 h and then seeded on plastic plates or poly-HEMA coated plates for 24 h. Immunoblotting analysis was performed with anti-PTK6, P-FAK (Tyr576/Tyr577), P-FAK (Tyr925), FAK, P-AKT (Ser473), P-AKT (Thr308), AKT, CC3, p27 and b-catenin antibodies. (c) Knockdown of PTK6 promotes PC3 cells to undergo anoikis. PC3 cells transfected with siRNAs against PTK6 or control were seeded on poly-HEMA coated plates for indicated periods. Cell viability was measured by CellTiter-Glo luminescent assays. (d, e) Expression of FAK is able to rescue PTK6 knockdown-induced anoikis. PC3 cells were transfected with PCDNA3-HA-FAK or control plasmids for 24 h, and then transfected with PTK6 siRNAs or control siRNAs for 24 h. Cells were trypsinized and seeded on poly-HEMA coated plates (day 1). Protein lysates were harvested at day 2, and anoikis assays were performed at day 4 and day 6. Figure 6 . PTK6/FAK signaling is important in regulating anoikis resistance of PC3 cells. (a, b) SRC and FAK are efficiently knocked down by siRNAs in PC3 cells. PC3 cells were transfected with siRNAs against PTK6, SRC, FAK or control siRNAs for 24 h and then seeded on poly-HEMA coated plates (day 1). Protein lysates were harvested at day 2, and immunoblotting was performed with anti-PTK6, SRC, FAK and b-catenin antibodies. Expression of b-catenin serves as a loading control. (c) PTK6 is primarily responsible for anoikis resistance of PC3 cells. Anoikis assays were performed using various knockdown cells described in a, b after 120 h of suspended growth on poly-HEMA coated plates (day 6). (d) A proposed model shows how PTK6 regulates cell survival. When cells detached from extracellular matrix, membrane-associated active PTK6 is able to phosphorylate and activate FAK and following AKT survival signaling. PTK6 is also able to protect cells from anoikis independent of FAK, probably through direct phosphorylation and activation of AKT. 13 PTK6 phosphorylates FAK Y Zheng et al inhibition and anchorage dependence, as well as their resistance to anoikis and tumor forming ability in vivo (Figure 3 ). AKT has a critical role downstream of PTK6 in survival signaling, as Palm-PTK6-YF fails to protect Akt1/2 À / À MEFs against anoikis, which show greater sensitivity to apoptosis under suspended growth conditions compared with SYF and Fak À / À MEFs (Figures 4c and e; data not shown). In Fak À / À MEFs, overexpression of FAK is able to provide protection for cells lacking signals from extracellular matrix, while co-expression of FAK and Palm-PTK6-YF induces stronger FAK and AKT activation and synergistically promotes cell survival (Figures 4b and c) . Expression of Palm-PTK6-YF alone also shows some protective effect, indicating that the constitutively active PTK6 is able to activate survival signaling independent of FAK (Figures 4b and c ). This is probably through directly phosphorylating AKT at tyrosine residues and thereby lowering sensitivity to growth receptor signaling (Figure 6d ). 13 Metastatic prostate cancer is the second leading cause of cancer-related deaths in American men. Increased PTK6 expression is detected in human primary and metastatic prostate cancers, and this is accompanied by the loss of its nuclear localization. 4, 5 Cytoplasmic retention of PTK6 promotes proliferation and migration of prostate tumor cells, while nuclear-targeted PTK6 negatively regulates cell growth. 5, 45 Relocalization of PTK6 from the nucleus to the cytoplasm might facilitate the activation of PTK6 by integrin and growth factor receptor signaling, as well as its access to cytoplasmic substrates such as AKT, p130CAS, Paxillin, p190RhoGAP, epidermal growth factor receptor and FAK, therefore promoting cancer cell proliferation, migration and survival. 5, [11] [12] [13] [14] Here, we showed increased activation of both PTK6 and FAK at plasma membrane in Pten-null prostate tumor cells (Figure 5a ), which may positively regulate tumorigenesis and metastasis. A more detailed study addressing the significance of PTK6 relocalization and activation at the membrane in prostate tumor cell metastasis is currently underway.
Resistance to anoikis is a characteristic of metastatic cancer cells, allowing them to escape death under adverse conditions. Cancer cells escape anoikis primarily through regulating the extrinsic death receptor pathway and the extracellular matrixintegrin-mediated cell survival pathway (reviewed in Brauer et al. 46 ). Different strategies that target various players in integrin/SRC/FAK/AKT survival signaling have shown promise in inhibiting tumor growth in vitro and in vivo (reviewed in Brauer et al. 46 and Sakamoto and Kyprianou 47 ). In our study, metastatic PC3 prostate cancer cells display the ability to escape from anoikis, and have a 90% viability rate after 8 days of growth on poly-HEMA coated plates (Figure 5c ). Apoptosis is not induced, but levels of p27 are substantially increased upon detachment (Figure 5b ), contributing to cell cycle arrest and promoting cell survival. 48 Knockdown of PTK6 induces apoptosis under suspended growth conditions, and cell viability decreases to about 20% (Figure 5b , CC3; 5c).
PTK6 shares several direct substrates with SRC, including AKT, p130CAS, p190RhoGAP, Paxillin and FAK, indicating they may have redundant functions. 5, 11, 13, 14 Importantly, here we demonstrated that it is PTK6, but not SRC, that has crucial roles in protecting prostate cancer cells from anoikis (Figures 6a and c) . PTK6-induced FAK phosphorylation and subsequent AKT activation appears critical for the survival of cancer cells in the absence of correct extracellular stimuli, and highlights the potential for combinational cancer therapeutics that target integrin signaling and PTK6 in human prostate cancer.
MATERIALS AND METHODS Antibodies
Anti-human PTK6 (C-18), anti-mouse PTK6 (C-17), anti-FAK (C-20), and antiphosphotyrosine (PY20) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phosphotyrosine (4G10), anti-SRC (GD11) and anti-P-PTK6 (Tyr342) antibodies were purchased from Millipore (Bedford, MA, USA). Antibodies directed against AKT, P-AKT (Thr308), P-AKT (Ser473), P-FAK (Tyr925), P-FAK (Tyr576/Tyr577), CC3 (Asp175), HA-tag (6E2) and Myc-tag (9B11) were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibodies directed against p27 and b-catenin were obtained from BD Pharmingen (San Diego, CA, USA). Anti-P-paxillin (Tyr118) antibodies were obtained from Invitrogen (Carlsbad, CA, USA). Anti-b-actin (AC-15) antibodies were purchased from Sigma-Aldrich (St Louis, MO, USA). Anti-GST tag antibody was purchased from Covance (Cumberland, VA, USA). Donkey anti-rabbit or sheep anti-mouse antibodies conjugated to horseradish peroxidase were used as secondary antibodies (Amersham Biosciences, Piscataway, NJ, USA) and detected by chemiluminescence with SuperSignal West Dura extended duration substrate from Pierce (Rockford, IL, USA).
Plasmids and siRNAs
Myc-tagged full-length human active PTK6 (YF) in the pcDNA3 vector and the Myc-tagged human PTK6-YF and Palm-PTK6-YF constructs in pBABEpuro vector have been described. 5, 13 Coding sequences of Palm-PTK6-YF were subcloned into the pBABE-hygro vector (Cell Biolabs Inc., San Diego, CA, USA). The GST-PTK6 (mouse) constructs were previously described. 13 A pcDNA3-HA-FAK (mouse) plasmid was a gift from Dr David Schlaepfer (UCSD, San Diego, CA, USA). Coding sequences of mouse FAK were amplified by PCR and subcloned into the pBABE-puro vector. Dicersubstrate siRNAs (DsiRNAs) against PTK6 were purchased from the IDT predesigned DsiRNA library (IDT, Coralville, IA, USA). The sequence for Dsi-PTK6 is: 5 0 -AGGTTCACAAATGTGGAGTGTCTGC-3 0 . The sequence for Dsi-FAK is 5 0 -GCAATGGAGCGAGTATTAAAGGACT-3 0 . The sequences for Dsi-SRC are 5 0 -CCCUUCGAGAUCAUCACUUCCUUGC-3 0 , and 5 0 -AGAGAACCUGG UGUGCAAAGUGGCC-3 0 .
Cell culture and transfections
The human embryonic kidney cell line 293 (HEK-293) (ATCC CRL-1573), the MEF cell line SYF (ATCC CRL-2459), the Fak À / À MEF cell line (ATCC CRL-2644), the human colon cancer cell line SW620 (ATCC CCL-227), the human prostate cancer cell line PC3 (ATCC CRL-1435) and the human breast cancer cell lines T47D (ATCC HTB-133) and MDA-MB-231 (ATCC HTB-26) were cultured in recommended medium according to ATCC guidelines. Akt1/2 À / À MEF cells immortalized by DN-p53 (kindly provided by Dr Nissim Hay, University of Illinois at Chicago, Chicago, IL, USA) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. 49 Transfections were performed using the Lipofectamine 2000 transfection reagent (Invitrogen) as per the manufacturer's instructions.
Retrovirus production and transduction pBABE-puro or pBABE-hygro plasmids were transfected into Phoenix-Eco cells using Lipofectamine 2000 (Invitrogen). Retrovirus was collected 48 and 72 h later. MEF cells were infected with retrovirus at a multiplicity of infection of 100 for 24 h. Stable cell pools were selected in growth medium containing 2 mg/ml puromycin or 100 mg/ml hygromycin B for a week.
Protein lysates, IP and GST pull down assay
Transfected cells were lysed in 1% Triton X-100 lysis buffer (1% Triton X-100, 20 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM ethylene glycol tetraacetic acid, 10 mM Na-pyrophosphate, 100 mM NaF, 5 mM iodoacetic acid, 0.2 mM phenylmethylsulfonyl fluoride, protease inhibitor cocktail (Roche, Indianapolis, IN, USA)) 18-24 h after transfection. Procedures for IPs and GST pull down assays were described previously. 5 Samples were subjected to SDS-polyacrylamide gel electrophoresis and transferred onto Immobilon-P membranes for immunoblotting. For large-scale IP, tyrosine phosphorylated proteins were immunoprecipitated from 10 mg soluble SW620 cell lysates in Triton X-100 buffer. Samples were subjected to SDS-polyacrylamide gel electrophoresis gels and stained with Coomassie Brilliant Blue R-250 (Bio-Rad, Hercules, CA, USA). Three distinct bands at B120, 80 and 68 kDa were excised for tandem mass spectrometry sequencing. 
In vitro kinase assays
Tandem mass spectrometry (LC/MS/MS)
Samples were subjected to in-gel digestion using sequencing grade trypsin followed by C 18 reversed-phase microcapillary liquid chromatographytandem mass spectrometry using a hybrid linear ion trap-Orbitrap XL mass spectrometer (Thermo Scientific, Waltham, MA, USA) in positive-ion datadependent acquisition mode. MS/MS spectra were searched against the reversed and concatenated Swiss-Prot protein database using the Sequest algorithm (Proteomics browser; Thermo Scientific) with differential modifications for serine, threonine and tyrosine phosphorylation (79.97) and methionine oxidation (15.99) . Phosphorylation sites were identified if they initially passed the following Sequest scoring thresholds: 2 ions, XcorrX1.90, SfX0.4, P40; 3 ions, XcorrX2.55, SfX0.5, P40 against the forward database. Peptides with gas phase charges of 1 and 4 were generally not accepted because of difficulty of interpretation. Passing MS/MS spectra were then manually validated to ensure that all b-and y-fragment ions aligned with the assigned modified protein sequence. Determination of the exact sites of phosphorylation was aided using GraphMod software (Proteomics Browser Software, Thermo Scientific), resulting in a false-positive identification rate of o1.2%.
Proliferation, soft agar and transformation assays
For proliferation assays, subconfluent cells were seeded in triplicate for each time point at a density of 2 Â 10 3 per well in 48-well plates. The fold increase of cell number was measured by the CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI, USA). For soft agar assays, 5 Â 10 3 cells were seeded in triplicate on the top layer of six-well plates, which contained 0.35% agar in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. The bottom layer of soft agar contained 0.7% agar in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Cells were fed twice a week, and colonies were counted at three weeks post plating. For transformation assays, 5 Â 10 3 cells of the line to be tested were mixed with 1 Â 10 5 untransformed SYF cells, plated into sixwell dishes, maintained at confluence and scored for foci after 10 days.
Anoikis assays
MEFs were trypsinized and plated onto poly-HEMA coated 10 cm plates in growth medium to prohibit attachment. Cells were transfected with siRNAs for 24 h, and then seeded at poly-HEMA coated plates in growth medium. Viability of the cells was measured every other day by the CellTiter-Glo luminescent cell viability assay (Promega). The cells were harvested with Triton X-100 lysis buffer at indicated time.
Immunostaining
Cells were washed with PBS and fixed in Carnoy's solution (60% ethanol, 30% chloroform, 10% acetic acid), and then blocked with 3% bovine serum albumin for 1 h and incubated with primary antibodies overnight. After washing, samples were incubated with fluorescein isothiocyanate-conjugated anti-mouse secondary antibodies or rhodamine-conjugated antirabbit secondary antibodies (Sigma-Aldrich). Rhodamine-conjugated phalloidin was used to selectively stain F-actin as per the manufacturer's instructions (Invitrogen). Slides were mounted in Vectashield fluorescent mount media containing 4 0 , 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA). Murine prostate tumor model and immunohistochemistry C57BL/6J PTEN flox/flox Probasin-Cre fixed mouse tissues were provided by Dr Nissim Hay. 40 Mice were killed at 6 months and prostates were formalinfixed and paraffin-embedded. Antigen retrieval was performed in 10 mM sodium citrate buffer on heat plate with a temperature above 90 1C for 20 min. Immunohistochemistry was performed using the VECTASTAIN Elite ABC Kit (rabbit IgG) (Vector Labs) as per the manufacturer's instructions. Reactions were visualized with fluorescein isothiocyanate or rhodamineconjugated avidin. Slides were mounted in Vectashield fluorescent mount media containing DAPI (Vector Laboratories). Tissues were then observed using standard UV, rhodamine or fluorescein isothiocyanate filters under Â 40 water-immersion objectives by the Carl Zeiss LSM 700 laser scanning microscope. Images were obtained with Axiocam HRc Color Digital Camera and LSM 700's ZEN software (Carl Zeiss, Jena, Germany).
Xenograft model SYF cells stably expressing vector or Palm-PTK6-YF were trypsinized and resuspended in 4 Â 10 7 cells/ml in PBS. Male nude Mice (CrTac:NCr-Foxn1 nu , Taconic, Germantown, NY, USA), 10 weeks of age, were anesthetized with a ketamine/xylazine mix. 3 Â 10 6 Palm-PTK6-YF expressing SYF cells in a volume of 150 ml (1:1 mixed with Matrigel (BD Biosciences, San Jose, CA, USA)) were injected subcutaneously in the left flank. The same number of vector expressing SYF cells was injected in the right flank as controls. Mice were killed 4 weeks after injection.
Statistics
For all the cell studies, data represent the mean of at least three independent experiments ± s.d. P-values were determined using the two tailed Student's t-test (Microsoft Excel 2010). A difference was considered statistically significant if the P-value was p0.05.
